Thanks for looking at that! I am really curious because I have never seen anywhere that having a low HBA1C could be an issue.

We are unable to estimate our long-term capital requirements due to uncertainties associated with the development and commercialization of Aramchol. If we fail to obtain necessary funds for our operations, we will be unable to develop and commercialize Aramchol and any future product candidates.

Thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen content (FIB) were examined with commercial kits following the manufacturer’s instructions by a coagulometer (Jiancheng, Nanjing, China). TT was determined by incubating 50 μl plasma solution for 3 min at 37 °C, followed by addition of 100 μl thrombin agent. PT was determined by incubating 50 μl plasma solution for 3 min at 37 °C, followed by addition of 100 μl thromboplastin agent. APTT was determined by incubating 50 μl plasma with 50 μl APTT activating agent for 3 min at 37 °C, followed by addition of 50 μl CaCl2. FIB was determined by incubating 10 μl plasma with 90 μl imidazole buffer for 3 min at 37 °C, followed by addition of 50 μl FIB agent. The anticoagulation activity was assessed by assaying the prolongation of the plasma clotting time of TT, PT, APTT, and reduction of FIB content.

We determined that the transaction price at contract inception was $2.1 million consisting of the upfront, non-refundable payment. None of the clinical or regulatory milestones were included in the transaction price upon inception, as all milestone amounts were fully constrained. Management assessed that the likelihood of occurrence of the other performance obligations in the Samil Agreement was remote upon contract inception. As such, the standalone value of such performance obligations was deemed de minimis and none of the transaction price was allocated to those obligations. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, and therefore have also been excluded from the transaction price.

The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights, distributions or other matters and shares having preemptive rights. As of the date hereof, no preferred shares are authorized under our Articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our Articles, which requires the affirmative vote of at least 75% of the voting rights of the Company represented personally or by proxy and voting thereon at a general meeting at which a quorum is present. The convening of the general meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Articles and the Companies Law as described above in “— Shareholder Meetings.”

Aspirin has a number of other mechanisms than COX inhibition (as you pointed out Josh), one of which is that people who take it for a long period of time have lower iron levels, some 25% or more lower. This happens because aspirin promotes minor intestinal bleeding, and possibly also because aspirin directly chelates iron. (The chemical assay for salicylates involves adding ferric chloride to a solution, which binds to salicylate and turns blue.) Iron lowering could account for much of aspirin’s anti-cancer activity and some of it’s long-term CVD prevention. Salicylate is among the most powerful iron chelators and is in fact used by some species of bacteria to grab iron from their host. Willow bark extract was found by Titorenko and colleagues to be the most powerful life-extension substance on yeast yet found, and of course willow bark contains salicylate.

Our Articles provide, as allowed by the Companies Law, that any director may, subject to the conditions set thereto, appoint a person as an alternate to act in his place, to remove the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of the board of directors so long as he or she is not already serving as a member of such committee, and if the alternate director is to replace an external director, he or she is required to be an external director and to have either “financial and accounting expertise” or “professional expertise,” depending on the qualifications of the external director he or she is replacing. A person who does not have the requisite “financial and accounting experience” or the “professional expertise,” depending on the qualifications of the external director he or she is replacing, may not be appointed as an alternate director for an external director. A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate director of an independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director or terminates the appointment.

(a, c) Representative images of wound-healing assay showing migration of rat PASMC either with miR-322 overexpression or knockdown. (b, d) Bar chart showing relative decreased wound width after 24 h. Data are shown as mean ± SD. *p < 0.05 compared to miR-Con or anti-Con.

You are very sharp to pick up on my passing comment Alan, and I would value your opinion and input on this possible intervention.

The second patent family discloses and claims additional FABACs with different conjugation moieties, as well as the use of these and the compounds disclosed in the first patent family above, including Aramchol, in the treatment of fatty liver, reduction of serum cholesterol and treatment of hyperglycemia and diabetes. This patent family includes a U.S. patent directed to the treatment of fatty liver a U.S. patent directed to reduction of serum cholesterol by administering additional forms of FABACs, and a U.S. patent (Continuation-in-Part) directed to the treatment of hyperglycemia and diabetes. This patent family also includes two European patents, one patent which was validated in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom, and the second patent which was validated in Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey and the United Kingdom. The family also includes patents in Australia, Canada, China, Czech Republic, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Russian Federation, Indonesia, Japan, Korea, Israel, Mexico, New Zealand, Norway, Poland, Hungary and the Ukraine. A foreign patent application is pending in the Czech Republic. If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended patent term for this patent family is due to expire on April 15, 2022, with the exception of the Israeli patent, which is due to expire on April 17, 2021. The terms of the U.S. patents in this family have been extended due to patent term adjustments of 567 days for U.S. Patent 7,501,403, which is directed to the treatment of fatty liver, and 24 days for U.S. Patent 8,110,564, which is directed to reduction of serum cholesterol, and 356 days for U.S. Patent 8,975,246, which is directed to disorders associated with altered glucose metabolism or insulin action.

Custodis, F., Eberl, M., Kilter, H., Bohm, M. & Laufs, U. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy. Cardiovasc. Res. 71, 342–351, 10.1016/j.cardiores.2006.04.005 (2006).

Bachem has announced that the company has concluded an agreement with Atheris Laboratories to market their Melusine® libraries, consisting of natural products isolated from animal venoms. The agreement includes services to assist customers with the identification of the active ingredients a